PACIRA BIOSCIENCES, INC.
PCRX · NASDAQ
Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local analgesic, EXPAREL ® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera° system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves.
ESG Scores
Overall ESG3.4
Environmental2.4
Social3.0
Governance4.6
Gender Diversity
Female Directors0.11109999999999999%
Female Executives0.011887072808320952%
Women in Workforce0.429%
CEO GenderMale